Skip to content
OpenCapital
Get started

Eton Pharmaceuticals, Inc. ETON Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K—
Free cash flow$7.3M+251%

Valuation

See full
Market cap$930.79M+162%
Enterprise value$942.39M+156%
P/S10.7×+3.4×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%—
Net margin-9.5%-2.7pp
FCF margin17.1%—

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity1×-0.2×
Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s proceeds from issuance of common stock relating to employee stock plans?
Eton Pharmaceuticals, Inc. (ETON) reported proceeds from issuance of common stock relating to employee stock plans of $1.39M in Q1 2026.
How has Eton Pharmaceuticals, Inc.'s proceeds from issuance of common stock relating to employee stock plans changed year-over-year?
Eton Pharmaceuticals, Inc.'s proceeds from issuance of common stock relating to employee stock plans increased by 252.5% year-over-year, from $394K to $1.39M.